1. | aquarian450202 | |
2. | crofoothill | |
3. | nellynat6 | |
4. | lsccbean | |
5. | mmcc3439 |
1. | aquarian450202 | |
2. | crofoothill | |
3. | nellynat6 | |
4. | lsccbean | |
5. | mmcc3439 |
1. | aquarian450202 02/21/2018 bull momentum |
2. | nellynat6 02/21/2018 What's happening today? |
3. | aquarian450202 11/12/2018 Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500 |
4. | crofoothill 02/21/2018 Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors |
5. | crofoothill 05/11/2018 Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress |
6. | nellynat6 05/06/2018 Files for $150 mln mixed securities shelf offering |
7. | aquarian450202 02/26/2018 Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy |
8. | lsccbean 02/21/2018 I'm in. |